Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 132, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2020.110888
Keywords
MUC1-based vaccine; Clinical trials; Infection-associated cancers
Funding
- National Natural Science Foundation of China [31360225]
- Sichuan Science and Technology Program [2019YFN0134]
- Fundamental Research Funds for the Central Universities [2682018CX73]
Ask authors/readers for more resources
Mucin 1 (MUC1) is a transmembrane mucin glycoprotein expressed on the surface of almost all epithelial cells. Aberrantly glycosylated MUC1 is associated with cellular transformation from a normal to malignant phenotype in human cancers. Therefore, MUC1 is the major target for the design and development of cancer vaccines. MUC1-based cancer vaccines are a promising strategy for preventing cancer progression and metastasis. This review summarizes the most significant milestones achieved to date in the development of different MUC-1based vaccine approaches in clinical trials. Further, it provides perspectives for future research that may pro mote clinical advances in infection-associated cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available